Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2025-02-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kyungbo Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities and financial statements for the 38th fiscal year. This type of document is standard for providing shareholders with the necessary information to vote on board appointments, dividend approvals, and financial reports, which falls under the category of Proxy Solicitation & Information Statement.
2025-02-25 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Statement or Proxy Solicitation). It contains information regarding the upcoming Annual General Meeting (AGM), including agenda items like the approval of financial statements, election of directors, and remuneration limits. This document is specifically designed to solicit votes from shareholders for the meeting, fitting the definition of a Proxy Solicitation & Information Statement.
2025-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the acquisition of shares by an executive (Kim Tae Young) of Kyongbo Pharmaceutical. This type of filing, which reports personal share transactions by company directors and executives, is classified as 'Director's Dealing'.
2025-02-11 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a '최대주주등소유주식변동신고서' (Report of Change in Shareholding by Major Shareholders and Related Parties) filed by Kyongbo Pharmaceutical. It details specific share transactions (purchases) by company executives and major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels and insider holdings.
2025-02-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Chong Kun Dang Holdings) and special related parties in the company 'Kyungbo Pharmaceutical'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2025-02-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Director's Dealing' or 'Insider Trading' report) where company executives disclose changes in their shareholdings. It identifies the reporter (Jung Hee Rok), their position (Director), and details the transaction (market purchase of shares). This fits the 'Director's Dealing' (DIRS) category perfectly.
2025-02-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.